Role of stent design and coatings on restenosis and thrombosis.

More than 15 years have passed since stent technology was introduced by Sigwart et al. [U. Sigwart, J. Puel, V. Mirkovitch, F. Joffe, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Engl. J. Med. 316 (1987) 701-706.] among interventional cardiologists. Recently drug eluting stents have assumed dominance in the interventional world as positive trial results revealed their efficacy for preventing restenosis. Stent design, delivery-vehicle materials, and drug properties affect the function of these stents. Stainless steel stents with tubular and multicellular design have proven superior to coil or hybrid stent models. This chapter describes stents which have subtle influences of modular design, metal coverage, strut thickness, strut shape, surface smoothness, and coating materials like an alloy composition.

[1]  M. S. Williams,et al.  Stent and artery geometry determine intimal thickening independent of arterial injury. , 2000, Circulation.

[2]  E. Edelman,et al.  Endovascular stent design dictates experimental restenosis and thrombosis. , 1995, Circulation.

[3]  S. Silber,et al.  The NUGGET study: NIR ultra gold‐gilded equivalency trial , 2004, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[4]  Heparin-Coated Stent Placement for the Treatment of Stenoses in Small Coronary Arteries of Symptomatic Patients , 2003 .

[5]  Gregg W Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[6]  Y. Matsumoto,et al.  Does stent design affect probability of restenosis? A randomized trial comparing Multilink stents with GFX stents. , 2001, American heart journal.

[7]  H. Crijns,et al.  Silicon-carbide coated coronary stents have low platelet and leukocyte adhesion during platelet activation. , 1999, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[8]  P. Dobesh,et al.  Drug‐Eluting Stents: A Mechanical and Pharmacologic Approach to Coronary Artery Disease , 2004, Pharmacotherapy.

[9]  P. Gurbel,et al.  Could stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) Study. , 2002, The Journal of invasive cardiology.

[10]  C. Di Mario,et al.  In-stent restenosis in small coronary arteries: impact of strut thickness. , 2002, Journal of the American College of Cardiology.

[11]  H Shimokawa,et al.  Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. , 1998, Journal of the American College of Cardiology.

[12]  R. Virmani,et al.  Pathology of acute and chronic coronary stenting in humans. , 1999, Circulation.

[13]  K. Mak,et al.  Clinical impact of stent construction and design in percutaneous coronary intervention. , 2004, American heart journal.

[14]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[15]  M. Fishbein,et al.  Subacute thrombosis and vascular injury resulting from slotted-tube nitinol and stainless steel stents in a rabbit carotid artery model. , 1996, Circulation.

[16]  A. Colombo,et al.  Biodegradable stents : "fulfilling the mission and stepping away". , 2000, Circulation.

[17]  C. Di Mario,et al.  Emergency Polytetrafluoroethylene-Covered Stent Implantation to Treat Coronary Ruptures , 2000, Circulation.

[18]  S Sawada,et al.  Reaction of the aortic wall to six metallic stent materials. , 1995, Academic radiology.

[19]  A. Kastrati,et al.  Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial , 2001, Circulation.

[20]  C. Thalhammer,et al.  Percutaneous treatment of pseudoaneurysms and arteriovenous fistulas after invasive vascular procedures , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[21]  F Joffre,et al.  Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.

[22]  C. Di Mario,et al.  Randomized Evaluation of Polytetrafluoroethylene‐Covered Stent in Saphenous Vein Grafts: The Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial , 2003, Circulation.

[23]  J. E. Sousa,et al.  Randomized intravascular ultrasound comparison between patients that underwent amorphous hydrogenated silicon-carbide coated stent deployment versus uncoated stents , 2003 .

[24]  R. Virmani,et al.  Nonbiodegradable Expanded Polytetrafluoroethylene-Covered Stent Implantation in Porcine Peripheral Arteries: Histologic Evaluation of Vascular Wall Response Compared with Uncoated Stents , 2001, CardioVascular and Interventional Radiology.

[25]  R E Vlietstra,et al.  Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. , 1992, Journal of the American College of Cardiology.

[26]  M. Leon,et al.  Safety of an Aspirin-Alone Regimen After Intracoronary Stenting With a Heparin-Coated Stent: Final Results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) Study , 2003, Circulation.

[27]  M. Jeong,et al.  Comparison of gold-coated NIR stents with uncoated NIR stents in patients with coronary artery disease. , 2002, The American journal of cardiology.

[28]  A. Tárnok,et al.  Rapid in vitro biocompatibility assay of endovascular stents by flow cytometry using platelet activation and platelet-leukocyte aggregation. , 1999, Cytometry.

[29]  J. Tanguay,et al.  Current status of biodegradable stents. , 1994, Cardiology clinics.

[30]  Robert C. Eberhart,et al.  Bioresorbable Microporous Stents Deliver Recombinant Adenovirus Gene Transfer Vectors to the Arterial Wall , 1998, Annals of Biomedical Engineering.

[31]  Gregg W Stone,et al.  One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial , 2004, Circulation.

[32]  G. Stone,et al.  Advanced c‐myc antisense (AVI‐4126)‐eluting phosphorylcholine‐coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model , 2004, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[33]  N. Kløw,et al.  Elective placement of covered stents in native coronary arteries , 2003, Acta radiologica.

[34]  H. Bøtker,et al.  Randomized comparison of the coil‐design Crossflex and the tubular NIR stent , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[35]  M. Tabrizian,et al.  Nitinol versus stainless steel stents: acute thrombogenicity study in an ex vivo porcine model. , 2002, Biomaterials.

[36]  Raimund Erbel,et al.  Drug-eluting bioabsorbable magnesium stent. , 2004, Journal of interventional cardiology.

[37]  A. Küttner,et al.  Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. , 1997, Circulation.

[38]  R. Virmani,et al.  Preclinical restenosis models and drug-eluting stents: still important, still much to learn. , 2004, Journal of the American College of Cardiology.

[39]  P. Hugenholtz,et al.  Silicon carbide‐coated stents in patients with acute coronary syndrome , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[40]  L. Buellesfeld,et al.  ABT-578-Eluting Stents , 2004, Herz.

[41]  J. Wataha,et al.  Ability of Ni-containing biomedical alloys to activate monocytes and endothelial cells in vitro. , 1999, Journal of biomedical materials research.

[42]  E. Edelman,et al.  Physiological Transport Forces Govern Drug Distribution for Stent-Based Delivery , 2001, Circulation.

[43]  E. Topol,et al.  Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. , 1996, Circulation.

[44]  J. J. Griffin,et al.  Clinical and angiographic follow-Up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. , 1999, Circulation.

[45]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[46]  B. Rutherford,et al.  Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. , 2005, The American journal of cardiology.

[47]  Antonio Colombo,et al.  Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) , 1998, The Lancet.

[48]  Christian W Hamm,et al.  Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis , 2000, The Lancet.

[49]  N. Kipshidze,et al.  Perspectives of Drug-Eluting Stents , 2002, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[50]  R. Virmani,et al.  Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.

[51]  P. Fitzgerald,et al.  Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable Polymer , 2004, Circulation.

[52]  P. Cahalan,et al.  Heparin coating of tantalum coronary stents reduces surface thrombin generation but not factor IXa generation , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[53]  Campbell D K Rodgers.  Drug-eluting stents: role of stent design, delivery vehicle, and drug selection. , 2002, Reviews in cardiovascular medicine.

[54]  S. Pocock,et al.  A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .

[55]  F. Van de Werf,et al.  Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. , 1997, Circulation.

[56]  C. Vlachopoulos,et al.  Stents covered by autologous venous grafts: feasibility and immediate and long-term results. , 2000, American heart journal.

[57]  Ralf Degenhardt,et al.  Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: the Tenax versus Nir Stent Study's long-term outcome. , 2003, American heart journal.

[58]  Larry S. Dean,et al.  Randomized Comparison of GR-II Stent and Palmaz-Schatz Stent for Elective Treatment of Coronary Stenoses , 2000, Circulation.

[59]  D. Murdoch,et al.  The Sirolimus-Eluting Stent , 2022, Reactions Weekly.

[60]  C. Rogers.  Optimal stent design for drug delivery. , 2004, Reviews in cardiovascular medicine.

[61]  N. Kipshidze,et al.  Estrogen‐eluting, phosphorylcholine‐coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[62]  P. Whitlow,et al.  Percutaneous transluminal angioplasty of saphenous vein graft stenosis: long-term follow-up. , 1989, Journal of the American College of Cardiology.

[63]  J C Greenfield,et al.  Interventional cardiac catheterization at Duke Medical Center. , 1988, The American journal of cardiology.

[64]  H. Uehata,et al.  Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.

[65]  A. Kastrati,et al.  Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. , 2000, Circulation.

[66]  C. Remy,et al.  Endovascular Treatment of Peripheral Artery Disease with Expanded PTFE-Covered Nitinol Stents: Interim Analysis from a Prospective Controlled Study , 2002, CardioVascular and Interventional Radiology.

[67]  J. Palmaz,et al.  Influence of stent design and material composition on procedure outcome. , 2002, Journal of vascular surgery.

[68]  Bruce R. Brodie,et al.  Coronary Angioplasty with or without Stent Implantation for Acute Myocardial Infarction , 1999 .

[69]  J. van Humbeeck,et al.  Metallic surface modification. , 1998, Seminars in interventional cardiology : SIIC.

[70]  V. Hombach,et al.  Comparison of the heparin coated vs the uncoated Jostent--no influence on restenosis or clinical outcome. , 2001, European heart journal.